AI/ML Innovations Inc. (AIML.CN) trades at C$0.04 on the CNQ in Canada during market hours on 04 Mar 2026 and shows very low liquidity with 152,739.00 shares traded today. AIML.CN stock sits near its 50-day average and well below its 200-day average, reflecting weak momentum in this small-cap AI healthcare name. Investors seeking AI-exposure in healthcare should weigh the company’s patent-pending monitoring system against negative earnings and thin daily volume.

AIML.CN stock market snapshot and intraday flow

AI/ML Innovations Inc. (AIML.CN) opened at C$0.04 and has traded between C$0.04 high and C$0.03 low today on CNQ. The market cap stands at C$6,730,560.00 with 168,264,000.00 shares outstanding. Volume is 152,739.00 versus an average volume of 430,047.00, showing relVolume near 0.36, which highlights low liquidity and wider bid-ask risk for active trading.

AIML.CN stock business model and AI healthcare positioning

AI/ML Innovations Inc. develops a patent-pending personal health monitoring and management system using AI and ML, targeting caregivers and healthcare professionals. The company operates in Medical – Healthcare Information Services and trades on CNQ in Canada, which positions AIML.CN stock in the AI-healthcare niche where adoption depends on clinical validation and partner deals.

AIML.CN stock financials and valuation metrics

AIML.CN shows negative profitability with EPS -0.03 and a trailing PE of -1.33, reflecting losses. Price-to-sales is 35.00 and price-to-book is 4.58, which mark the stock as expensive relative to tangible book given its tiny revenue per share (0.00) and net loss per share (-0.03). The company reports a current ratio of 2.09, cash per share 0.01, and debt-to-equity 0.11, indicating modest liquidity on the balance sheet but weak operating cash flow metrics.

AIML.CN stock technicals and trading signals

Short-term technicals show RSI 59.24 and a 50-day average price near C$0.04, which suggests neutral momentum. The 200-day average is about C$0.05, indicating a downtrend over the longer term. On-chain indicators show a high days-sales-outstanding figure and unusual working capital cycles, which can matter for microcaps like AIML.CN stock when receivables or payables shift.

Meyka AI rates AIML.CN with a score out of 100

Meyka AI rates AIML.CN with a score out of 100 at 62.33 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The proprietary grade balances weak profitability and low liquidity against a modest cash position and a niche AI-healthcare product offering.

Risks and opportunities for AIML.CN stock

Key risks for AIML.CN stock include thin trading volume, negative margins, and reliance on product validation and partnerships to scale revenue. The company’s small market cap and days-sales-outstanding near 575.81 magnify execution risk. Opportunities include commercialization of its wearable and software stack if it secures pilot programs or licensing deals that raise recurring revenue and credibility in healthcare.

Final Thoughts

AIML.CN stock trades at C$0.04 on CNQ as of 04 Mar 2026, presenting a clear microcap profile: niche AI-healthcare technology, limited liquidity, and negative earnings. Meyka AI’s forecast model projects a 12-month scenario of C$0.02 to C$0.02 (yearly forecast C$0.02), which implies an approximate -45.65% downside versus today’s price of C$0.04; forecasts are model-based projections and not guarantees. For a practical price-target framework, we set a conservative 12-month base target at C$0.04, a bear target at C$0.02, and a bull target at C$0.08 if management secures scaling partnerships and improves revenue metrics. Investors considering AIML.CN stock should treat it as a high-volatility, speculative AI-healthcare holding and use tight position sizing, given the company’s negative EPS, high price-to-sales, and thin trading volumes. Meyka AI, an AI-powered market analysis platform, flags both the product opportunity and the material execution risk that will dictate returns over the next 12 months.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.